Live Breaking News & Updates on Janssen Cilag Limited

Stay updated with breaking news from Janssen cilag limited. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Janssen-Cilag seeks European approval for guselkumab in ulcerative colitis and Crohn's disease treatment

Janssen-Cilag International NV, a Johnson & Johnson company, today announced it has submitted applications to the European Medicines Agency (EMA) seeking to expand the Marketing Authorization Application for TREMFYA® (guselkumab) to include the treatment of adult patients with moderately to severely active ulcerative colitis and moderately to severely active Crohn’s disease. ....

David Lee , European Medicines Agency , Drug Administration , European Union , Janssen Cilag International , Marketing Authorization Application , Ludovic De Beaucoudrey , Senior Director , Therapeutic Area Lead , Janssen Cilag Limited , Global Therapeutic Area Head Immunology , Johnson Innovative , Disease Week Annual Meeting , United European Gastroenterology Week , Biologics License Application , Crohns Disease , Ulcerative Colitis ,

Johnson & Johnson submits regulatory applications to

Media contact:Sophie [email protected]+33 6 3178 8798Investor contact:Raychel [email protected] For European and UK. ....

United Kingdom , Region Flamande , David Lee , Sophie Daneau , Drug Administration , Japan Pharmaceuticals , Exchange Commission , European Union , Canadian Agency For Drugs Technologies In Health , Janssen Biotech Inc , Crohn Colitis Foundation , None Of Janssen Research Development , Devices Agency , Janssen Research Development , European Medicines Agency , Janssen Cilag International , Marketing Authorisation Application , Ludovic De Beaucoudrey , Senior Director , Therapeutic Area Lead , Janssen Cilag Limited , Global Therapeutic Area Head Immunology , Johnson Innovative , Disease Week Annual Meeting , United European Gastroenterology Week , Biologics License Application ,

Janssen To Adopt Johnson & Johnson Brand As The Company Celebrates 100 Years Of Operating In The UK

Janssen To Adopt Johnson & Johnson Brand As The Company Celebrates 100 Years Of Operating In The UK
menafn.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from menafn.com Daily Mail and Mail on Sunday newspapers.

High Wycombe , United Kingdom , Daisy Waycorporate , Johnson Medtech , Roz Bekker , Johnson Company , Johnson Innovative Medicine , Managing Director , Johnson Innovative Medicine United Kingdom , Pulmonary Hypertension , Innovative Medicine , Janssen Cilag Limited , External Communications ,

Johnson & Johnson receives positive CHMP opinion for

This positive CHMP opinion establishes amivantamab as a new option, and the first fully-human EGFR-MET bispecific antibody, in the first-line treatment of. ....

France General , Region Flamande , United States , Nicolas Girard , Henar Hevia , Institut Curie , Paris Saclay University , European Medicines Agency , European Society For Medical Oncology Congress , Exchange Commission , European Union , American Lung Association , Janssen Biotech Inc , European Medicines Agency Seeking Approval , European Commission , Committee For Medicinal Products Human Use , Janssen Cilag International , Janssen Research Development , Medicinal Products , Human Use , Professor Nicolas Girard , Medical Oncology , Thoracic Oncology , Respiratory Medicine , Senior Director , Area Lead ,

Johnson & Johnson : CARVYKTI®▼ (ciltacabtagene autoleucel; cilta-cel) is the first BCMA-targeted treatment approved by the European Commission for patients with relapsed and refractory multiple myeloma who have received at least one prior line of therapy

Media contact:

Investor contact:

. ....

United States , Region Flamande , Edmond Chan , Jenni Mildon , Ciltacabtagene Autoleucel , European Commission Grants Conditional Approval , Legend Biotech United States Inc , Janssen Biotech Inc , Drug Administration , American Society Of Clinical Oncology , European Commission , Janssen Cilag International , Chinese Company Legend Biotech To Develop Investigational , American Cancer Society , Committee For Orphan Medicinal Products , Janssen Research Development , Johnson Company , European Union , European Medicines Agency , Exchange Commission , Cilag International , Area Lead Haematology , Johnson Innovative , New England Journal , Professor Jes , San Miguel ,